Tetrahydropyrimidine derivatives display functional selectivity for M1 muscarinic receptors in brain

Drug Development Research

Volumn 40, Issue 2, 1997, Pages 171-184

  Messer Jr , William S ^a,b   Abuh, Yahaya F ^a   Ryan, Kevin ^a   Shepherd, Mary A ^a   Schroeder, Melanie ^a   Abunada, Sufyan ^a   Sehgal, Rupa ^a   El Assadi, Afif A ^a  

^a Ctr for Drug Design and Development   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Acetylcholine; Agonists; Alzheimer's disease; Brain; Memory

Indexed keywords

AMIDINE; ARECOLINE; CARBACHOL; CDD 0097; HEXAHYDROSILADIFENIDOL; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; OTENZEPAD; PIRENZEPINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; CELL LINE; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; CORE TEMPERATURE; DRUG RECEPTOR BINDING; IN VITRO STUDY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LACRIMATION; MALE; MOUSE; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; RAT; RECEPTOR AFFINITY; SALIVATION; TECHNIQUE;

EID: 1842367290     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199702)40:2<171::AID-DDR7>3.0.CO;2-I     Document Type: Article

References (71)

1. Andrews JS, Jansen JHM, Linders S, and Princen A (1994): Effects of disrupting the cholinergic system on short-term spatial memory in rats. Psychopharmacology 115:485-494.
2. Andrews JS, Jansen JHM, Linders S, Princen A, and Broekkamp CLE. (1995): Performance of four different rat strains in the autoshaping, two-object discrimination, and swim maze tests of learning and memory. Physiol Behav 57:785-790.
3. Arunlakshana O, Schild HO (1959): Some quantitative uses of drug antagonists. Br J Pharmacol 206:587-595.
4. Bartus RT, Dean RL, Beer B, and Lippa AS (1982): Cholinergic hypothesis of geriatric memory dysfunction: A critical review. Science 217:4080-417.
5. Baxter MG, Bucci DJ, Wiley RG, Gorman LK, and Gallagher M (1995): Selective immunotoxic lesions of basal forebrain cholinergic cells: Effects on learning and memory in rats. Behav Neurosci 109:714-722.
6. Beninger RJ, Wirsching BA, Jhamandas K, Boegman RJ, and ElDefrawy SR (1986): Effects of altered cholinergic function on working and reference memory in the rat. Can J Physiol Pharmacol 64:376-382.
7. Birdsall NJM, Buckley N, Doods H, Fukuda K, Giachetti A, Hammer R, Kilbinger H, Lambrecht G, Mutschler E, Nathanson N, North A, and Schwarz R (1989): Nomenclature for Muscarinic Receptor Subtypes Recommended by Symposium. Fourth International Symposium on Subtypes of Muscarinic Receptors, Wiesbaden, Germany.
8. Bonner TI, Buckley NJ, Young AC, and Brann MR (1987): Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527-532.
9. Bonner TI, Young AC, Brann MR, and Buckley NJ (1988): Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403-110.
10. Bymaster FP, Heath I, Hendrix JC, and Shannon HE (1993): Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Phannacol Exp Ther 267:16-24.
11. Caulfield MP, Higgens GA, and Straughan DW (1983): Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. J Phann Pharmacol 35:131-1332.
12. Chrobak JJ, Hanin I, and Walsh TJ (1987): AF64A (ethylcholine aziridinium ion), a cholinergic toxin, selectively impairs working memory in a multiple component T-maze task, Brain Res 414:15-21.
13. Chrobak JJ, Hanin I, Schmechel DE, and Walsh TJ (1988): AF64A-induced working memory' impairment: Behavioral, neurochemical and histological correlates. Brain Res 463:107-117.
14. Cortés R, Palacios JM (1986): Muscarinic cholinergic receptors subtypes in the rat brain. I. Quantitative autoradiographic studies. Brain Res 362:227-238.
15. Cortés R, Probst A, Tobler H-J and Palacios JM (1986): Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies. Brain Res 362:239-253.
16. Coyle JT, Price DL, and DeLong MR (1983): Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219:1184-1190.
17. 1-receptor agonists: Potential in t he treatment of Alzheimer's disease. CNS Drugs 3:467-481.
18. Davis P, Maloney AJF (1976): Selective loss of central chohlinergic neurons in Alzheimer's disease. Lancet 2:1403.
19. Davis RE, Doyle PD, Carroll RT, Emmerling MR, and Jaen J (1995): Cholinergic therapies for Alzheimer's disease: Palliative or disease altering? Arzneim-forsch/Drug Res 45:425-431.
20. Deutsch JA (1971): The cholinergic synapse and the site of memory. Science 174:788-794.
21. Doods HN, Mathy M-J, Davidsko D, van Charlodorp KJ, de Jonge A, and van Zwieten PA (1987): Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 242:257-262.
22. 1 receptors agonists. J Med Chem 36:842-847.
23. 1 muscarinic receptor agonists. J Med Chem 37:2774-2782.
24. Forray C, El-Fakahany EE (1990): On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex. Mol Pharniacol 37:893-902.
25. 2 receptor antagonist. Life Sci 38:1663-1672.
26. Gil DW, Wolfe BB (1985): Pirenzepine distinguishes between and inhibition receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase. J Pharmacol Exp Ther 232:608-616.
27. Goyal RK (1989): Muscarinic receptor subtypes: Physiology' and clinical implications. N Engl J Med 34:1022-1029.
28. 1 muscarinic antagonist pirenzepine. Psychopharmacology 93:470-476.
29. Hagan JJ, Jansen JHM, and Broekkamp CLE (1989): Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics. Psychopharmacology 98:347-356.
30. Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, and Hulme EC (1980): Pirenzepine distinguishes between different subclasses of miscarinic receptors. Nature 283:90-92.
31. Hammer R, Giachetti NA (1982): Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci 31:29912998.
32. Hollander E Mohs RC, and Davis KL (1986): Cholinergic approaches to the treatment of Alzheimer's disease. Br Med Bull 42:97-100.
33. Holley LA, Wiley RG, Lappi DA, and Sarter M (1994): Coritcal cholinergic deafferentation following the intracortical infusion of 192 IgG-saporin: A quantitative histochemical study. Brain Res 663:277-286.
34. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, Haga T, Haga K, Ichiyama A, Kangawa K, Kojima M, Matsuo H, Hirose T, and Numa S (1986a): Cloning, sequencing and expression of complementation DNA encoding and muscarinic acetylcholine receptor. Nature 323:411-416.
35. Kubo T, Maeda A, Sugimoto K, Akiba I, Mikami A, Takahashi H, Haga T. Haga K, Ichiyama A, Kangawa K, Matsuo H, Hirose T, and Numa S (1986): Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett 209:367-372.
36. Lambrecht G, Feifel R, Forth B, Strohmann C, Tacke R, and Mutschler E (1988): p-Fluoro-hexahydro-siladifenidol: The first Map-selective muscarinic antagonist. EurJ Pharmacol 152:193-194.
37. Lapchak, PA, Araujo DM, Quirion R, and Collier B (1989): Binding sites for 3H-AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res 496:285294.
38. Leanza G, Nilsson OG, Wiley RG and Bjorklund A (1995): Selective lesioning of the basal forebrain cholinergic system by intraventricular 192 IgG-saporin: Behavioral, biochemical and stereological studies in the rat. Eur J Neurosci 7:329-343.
39. Lin MT, Chen FF Chern YF, and Fung TC (1979): The role of the cholinergic system sin the central control of thermoregulation in rats. Can J Pliysiol Pharmacol 57:1205-1212.
40. Mash DC, Potter LT (1986): Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 19:551.
41. Messer WS Jr, Abuh YE Liu Y, Periyasamy S, Ngur DO, Edgar MAN, El-Assadi AA, Sbeih S, Dunbar PG, Roknich S, Rho T, Fang Z, Ojo B, Zhang H, Huzl JJ, III, and Nagy PI (1997): Synthesis and biological characterization of 1,4,5.6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists. J Med Chem 40:1230-1246.
42. 1 muscarinic receptors in representational memory. Nuerosci Lett 116:184-189.
43. Messer WS Jr, Dunbar PG (1996): Rationale for the design and development of amidine derivatives as selective muscarinic agonists. Muscarinic Agonists and the Treatment of Alzheimer's Disease. New York: R.G. Landes Co., pp 131-153.
44. 1 receptors. Bioorg Med Chem Lett 2:781-786.
45. Messer WS Jr, Ellerbrock BR, Smith DA, and Hoss W (1989): Regional differences in the binding of selective muscarinic antagonists to rat brain: Comparison with minimum energy conformations. J Med Chem 32:1164-1172.
46. Messer WS Jr, Hoss WP (1987): Selectivity of pirenzepine in the central nervous system. I. Direct autoradiographic comparison of the regional distribution of pirenzepine and carbamylcholine binding sites. Brain Res 407:27-36.
47. Messer WS Jr, Stibbe JR, and Bohnett M (1991): Involvement of the septohippocampal cholinergic system in representational memory. Brain Res 564:66-72.
48. Messer WS Jr, Thomas GJ, and Hoss WP (1987): Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory task. Brain Res 407:37-45.
49. Moos W, Davis RE, Schwarz RD, and Gamzu ER (1988): Cognition activators. Med Res Rev 8:353-391.
50. Ojo B, Dunbar PG, Durant GJ, Nagy PI, Huzl JJ, III, Periyasamy S, Ngur DO, El-Assadi AA, Hoss WP, and Messer WS Jr (1997): Synthesis and biochemical activity of novel amidine derivatives as m1 muscarinic receptor agonists. Bioorg Med Chem 4:1605-1615.
51. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, and Capon DJ (1987): Distinct primary structures, ligand-hinding properties and tissue-specific expression of four human muscarinic acetylcholiue receptors. EMBO J 6:3923-3929.
52. 2 muscarinic acetylcholine receptor. Science 236:600-605.
53. Richards MH (1991): Pharmacology and second messenger interactions of cloned muscarinic receptors. Biochem Pharmacol 42:1645-1653.
54. Richards MH, van Giersbergen PLM (1995): Human muscarinic receptors expressed in A9 L and CHO cells: Activation by full and partial agonists. BrJ Pharmacol 114:1241-1249.
55. Rossner S, Schliebs R, Perezpolo JR, Wiley RG and Bigl V (1995): Differential changes in cholinergic markers from selected brain regions after specific immunolesion of the rat cholinergic basal forebrain system. J Neurosci Res 40:31-43.
56. Salles J, Wallace MA, and Fain JN (1993): Differential effects of alkylating agents on the multiple muscarinic receptor subtypes linked to activation of phospholipase-C by carbachol in rat brain cortical membranes. J Pharmacol Exp Ther 264:521-529.
57. Sanchez C, Lembol HL (1994): The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice, Pharmacol Toxicol 74:35-39.
58. 1 muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem 35:2274-2283.
59. Schwarz RD, Davis RE, Jaen JC, Spencer CJ, Tecle H, and Thomas AJ (1993): Characterization of muscarinic agonists in recombinant cell lines. Life Sci 52:465-472.
60. Smith TL, Yamamura HI (1985): Carbachol stimulation of phosphatidic acid synthesis: Competitive inhibition by pirenzepine in synaptosomes from rat cerebral cortex. Biochem Biophys Res Commun. 130:282-285.
61. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljärvi L, Talasniemi S, Ryynänen M, and Riekkinen P, Sr (1995): A severe loss of choline acetyltransferase in the frontal cortex ol Alzheimer patients carrying apolipoprotein e4 allele. Neurosci Lett 187:79-82.
62. Summers WK, Majovski LV, Marsh CM, Tachild K, and Kling A (1986): Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315:1241-1245.
63. Thomas GJ (1984) Memory: Time binding in organisms. In Squire LR, Butters N (eds): Neuropsychology of Memory. New York: Guilford pp 374-384.
64. Thomas GJ Gash DM (1986): Differential effects of posterior septal lesions on dispositional and representational memory. Behav Nenrosci 100:712-719.
65. Thomas GJ, Spafford PS (1984): Deficits for representational memory induced by septal and cortical lesions (singly and combined) in rats. Behav Neurosci 98:394-404.
66. Torres EM, Perry TA, Blokland A, Wilkinson LS, Wiley RG, Lappi DA, and Dunnett SB (1994): Behavioral, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 63:95-122.
67. Waite JJ, Chen AD, Wardlow ML, Wiley RC, Lappi DA, and Thai LJ (1995): 192 Immunoglobulin g-saporin produces graded behavioral and biochemical changes accompanying the loss of cholinergic neurons of the basal forebrain and cerebellar purkinje cells. Neuroscience 65:463-476.
68. Wall SJ, Yasuda RP, Li M, and Wolfe BB (1991): Development of an antiserum against m3 muscarinic receptors-Distribution of m3-receptors in rat tissues and clonal cell lines. Mol Pharmacol 40:783-789.
69. Walsh TJ, Kelly RM, Dougherty KD, Stackman RW, Wiley RG, and Kutscher CL (1995): Behavioral and neurobiological alterations induced by the immunotoxin 192-IgG-saporin: Cholinergic and noncholinergic effects following icv injection. Brain Res 702:233-245.
70. 3H]-pirenzepine. Life Sci 34:139.5-1402.
71. Wang SZ, Elfakahany EE (1993): Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists. J Pharmacol Exp Ther 266:237-243.